Dr. Tania Dempsey: Mast Cells, Chronic Fatigue, & Hidden Inflammation | TUH #270

Dr. Dempsey’s published case series included 47 patients with MCAS diagnosed via consensus‑2 criteria and elevated urinary or blood mediators. Patients were already taking semaglutide or tirzepatide for other reasons (diabetes, weight loss), and she documented symptom changes. The “incredible improvement” spanned neurological, respiratory, gastrointestinal, and dermatological domains. She emphasizes that this is a direct immunomodulatory effect, not merely a consequence of weight loss. She and others are now exploring retatrutide because mast cells also express glucagon receptors, but data is still anecdotal.

Dr. Dempsey describes SOT as her favorite treatment. She explains that in the immune‑compromised state of MCAS, simply quieting mast cells isn’t enough; the infectious trigger must be reduced. SOT eliminates the need for prolonged courses of antibiotics, antivirals, or even strong herbal antimicrobials, many of which MCAS patients cannot tolerate. She notes that this is not yet widely available—she partners with a lab to create the tailored RNA—but she believes it represents the future of targeted immunotherapy for post‑infectious chronic illness and MCAS.

Dr. Dempsey explains that her center is studying the removal of PFAS (“forever chemicals”) and microplastics via TPE. They measure blood and urine pre‑ and post‑procedure and see toxin levels drop. She also sees the plasma become visibly clearer after successive treatments, suggesting successful removal of waste. She draws an analogy to Gary’s fish‑tank metaphor: sometimes you must remove the dirty water, not just add filters. She also uses a variant (Inuspheresis) where plasma is filtered and returned.

Dr. Dempsey calls thymosin alpha her “favorite one” among peptides for immune building. She notes that even though it isn’t directly aimed at fatigue, many patients report improved energy because the immune system is recovering. She highlights that it’s not just about killing pathogens; you need to rebuild the immune system so it can police infections in the long term. Gary Brecka adds that he believes immuno‑fatigue is a primary theory of aging, and restoring T‑cell function aligns with that philosophy.

Dr. Dempsey emphasizes that despite her love for natural medicine, for parasites “you need the drugs.” The parasitic theory of chronic disease is a recurrent theme in both speakers’ philosophies. She uses the analogy of Spider‑Man—parasites have suction cups and hide in the intestinal wall—so stool tests may be negative despite infection. Her finding of Cryptosporidium in immunocompetent‑appearing patients shocked her and changed her practice.

Dr. Dempsey notes that she has observed dramatic responses in many MCAS patients. Gary Brecka shares that when his daughter had POTS, he implemented red light therapy as part of a detox protocol, and it was one of the most impactful interventions. He now believes she likely had undiagnosed MCAS. The discussion highlights red light as a foundational, low‑risk therapy that can be combined with almost any other treatment.

Dr. Dempsey says she almost never encounters an MCAS patient without measurable gut dysbiosis, even if they report zero digestive complaints. She uses the Vibrant Wellness Gut Zoomer test because she finds it reliable. She emphasizes that supplementation must be individualized: some patients can gradually introduce sauerkraut for natural SCFAs, while others need a pure butyrate supplement. She uses IgG‑based products (bovine serum immunoglobulins) and colostrum (if dairy tolerated) to provide passive immunity and gut repair. She also addresses biofilms with enzymes like nattokinase.

Dr. Dempsey explains that, when she started practice 30 years ago, she was passionate about women’s health and saw many PCOS patients. After she identified the MCAS link, she began testing all PCOS patients for mast‑cell mediators. She says, “I would say … right now in my practice, 100% of patients with PCOS have mass activation syndrome so it is actually the same thing.” She clarifies that as a doctor she’s careful about saying 100%, but the pattern is so consistent that she considers them one condition. This view implies that treating PCOS should include mast‑cell stabilization (antihistamines, mast cell stabilizers, removal of triggers) rather than solely focusing on hormones.

Dr. Dempsey describes how she conducted her study: she took 47 patients with a formal MCAS diagnosis (met consensus‑2 criteria, had elevated mediators) who were on either semaglutide or tirzepatide (terepitide), and compared symptoms before and after. The improvement was “incredible across so many different parts of the body.” She explains that mast cells are covered in receptors that act like satellites scanning the environment. Among them are GLP‑1 and GIP receptors. When the drugs bind, they tell the mast cell “all is well, nothing to do, calm down.” This stabilizes the cell, so it stops releasing cytokines, histamine, and other inflammatory mediators, allowing the body to heal. She notes this is a direct effect, not secondary to weight loss, making it relevant for managing MCAS.

She states, “I see it probably in 75% of my patients. … But they're not HIV or cancer patients.” This observation leads her to conclude that mast cell activation syndrome and accompanying multi‑system inflammation suppress immunity to a degree that allows parasites that should be harmless to thrive. She uses this as a teaching point to emphasize that MCAS is not merely an allergic annoyance but a deep immune failure. Testing for parasites becomes a central part of her workup, and she uses aggressive drug protocols (ivermectin, albendazole, nitazoxanide) because natural herbs often fail.

Dr. Dempsey explains that a lab creates an RNA sequence that matches the DNA of the identified pathogen. The patient receives it, and it directly binds the pathogen’s genetic material, stopping multiplication and eventually killing the organism. She says it’s her “favorite treatment actually” because she can avoid many medications in her highly sensitive population. She mentions using it for Epstein‑Barr, Lyme, bartonella, and other chronic infections, and notes it allows targeted therapy without overwhelming the immune system. The approach is particularly exciting because it’s not a generic immune booster but a precision medicine tool.

Dr. Dempsey notes, “mass cells make hepin. … it's the one cell in the body that actually releases and manufactures hepin.” She connects this to women with severe menstrual bleeding: estrogen fluctuations activate mast cells, which then release heparin, thinning the blood and causing heavy flow. She says, “these women are like hemorrhaging … because the mass cells … are releasing hepin. Now that blood is thinner and it's coming out faster.” This insight suggests that antihistamines and mast cell stabilizers could help with heavy periods, particularly in women with other MCAS symptoms.